Search DIAN-TU Biospecimen Resource Requests

In order to avoid the situation where two investigators study the same research question, please search our database to determine if your topic has already been studied. If you find that your topic or a related topic has already been submitted, you may wish to contact the investigator to inquire about his/her findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID # (e.g. TU1004), the full request has been submitted and is either approved, disapproved or in process.

Displaying 1 - 25 of 32

Investigator:

Andrew Aschenbrenner

Title:

Establishing the utility and sensitivity of high-frequency cognitive assessments in Dominantly Inherited Alzheimer Disease.

Date of Request:

06/28/2024

Aim 1:

To quantify the cognitive effects of ADAD mutations, APOE genotype and AD biomarkers using a high-frequency cognitive assessment (HFCA) paradigm, the Ambulatory Research in Cognition (ARC) smartphone application.

Investigator:

NA

Title:

Disappearing ARIA-H Microhemorrhages

Date of Request:

06/27/2024

Aim 1:

Demonstrate that ARIA-H microhemorrhages may resolve, rather than persist over time

Investigator:

Klaus Romero

Title:

Model-informed drug development (MIDD) in Autosomal Dominant Alzheimer's Disease

Date of Request:

05/31/2024

Aim 1:

Our goal is to develop a comprehensive drug-disease-trial model across the entire disease continuum of Autosomal Dominant Alzheimer's Disease (ADAD). The drug-disease trial will serve as the foundation for a clinical trial simulation tool for ADAD

Investigator:

NA

Title:

Alzheimer’s Disease Clinical Trials: What have we learned from magnetic resonance imaging

Date of Request:

02/06/2024

Aim 1:

outline how MRI is used in eligibility and safety monitoring in AD clinical trials

Aim 2:

review use of advanced MR imaging techniques in AD clinical trials

Aim 3:

discuss opportunities for acceleration in MRI trial protocols

Investigator:

NA

Title:

Alzheimer’s Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for ARIA Monitoring

Date of Request:

02/06/2024

Aim 1:

Review key MRI sequences for ARIA monitoring

Aim 2:

Provide imaging recommendations for clinical practice

Aim 3:

Highlight role of the radiologist in identifying and communicating ARIA findings

Investigator:

jing zhang

Title:

Research on the value of multi-layer network characteristics in the brain of patients with early-onset AD in disease diagnosis

Date of Request:

01/06/2024

Aim 1:

Exploring the changes in multi-layer network characteristics of the brain in patients with early-onset AD

Aim 2:

Explore the value of multi-layer network features in disease diagnosis

Investigator:

Aschenbrenner

Title:

Quantifying the impact of ARIA on cognition measured with computerized testing.

Date of Request:

11/09/2023

Aim 1:

Determine if ARIA produces measurable effects on cognition and quantify the effect size.

Investigator:

Jorge J Llibre Guerra & Clara Vila-Castelar

Title:

Influence of biological sex in response to treatment in Autosomal Dominant Alzheimer’s Disease

Date of Request:

10/27/2023

Aim 1:

To describe sex differences in cognitive outcomes between women and men

Aim 2:

To investigate possible differences in PiB-PET, brain glucose metabolism, and structural atrophy rate of change between women and men.

Aim 3:

To compare fluid biomarker levels and rates of change between women and men in DIAN-TU double blind period of gantenerumab or solanezumab.

Investigator:

Colin Masters

Title:

Automated detection and reporting of amyloid-related imaging abnormalities (ARIA) with emerging Alzheimer's disease therapeutics

Date of Request:

10/12/2023

Aim 1:

To develop automated machine learning algorithms for detection and reporting of ARIA using serial MRI scans of patients who underwent treatment with an anti-Aβ antibody therapy.

Aim 2:

To identify the potential AD biomarkers that are associated with an increased risk of ARIA development.

Aim 3:

Determine the level of autoantibodies to Abeta in the baseline and follow up plasma who are being treated with an anti-Abeta antibody therapy.

Investigator:

NA

Title:

Review of ARIA in Japanese

Date of Request:

10/02/2023

Aim 1:

We want to use DIAN's images from an article in our review article

Aim 2:

We want to use the images to illustrate actual symptoms

Investigator:

Laurent Roybon

Title:

Models and therapies for Dominantly Inherited Alzheimer disease

Date of Request:

08/16/2023

Aim 1:

Generate humanized models of early and advanced AD cellular pathogenesis

Aim 2:

Use humanized models to explore a gene therapy for disease progression in AD

Investigator:

Randall Bateman

Title:

Proteomic Biomarkers in Autosomal Dominant Alzheimer’s Disease

Date of Request:

08/07/2023

Aim 1:

Define the landscape and temporal sequence of CSF and plasma proteomic changes in ADAD

Aim 2:

Determine how treatment with anti-amyloid immunotherapies affects levels of brain-based biomarkers in ADAD CSF and plasma

Aim 3:

Leverage proteomics data to provide biological pathway and systems context to experimental results generated in other DIAN projects

Investigator:

Junie Saint Clair

Title:

Examining the Predictive Value of Synaptic Dysfunction and Neuronal Injury Measures on Imaging Markers of Disease Presentation and Progression in Alzheimer's Disease

Date of Request:

08/01/2023

Aim 1:

Evaluate association between rates of longitudinal change in CSF levels of Ng, SNAP-25, VILIP-1 and imaging brain changes and cognition in a DIAD cohort.

Aim 2:

Evaluate association between rates of longitudinal change in CSF levels of Ng, SNAP-25, VILIP-1 and imaging brain changes and cognition in aged adults LOAD cohort.

Investigator:

Bart De Strooper

Title:

Testing the role of presenilins in cell states

Date of Request:

04/14/2023

Aim 1:

Profiling the gamma-secretase substrate proteome in PSEN1 H163R iPSC-derived microglia

Aim 2:

Characterizing the transcriptional and functional phenotype of human PSEN1 H163R microglia in a humanized chimeric AD mouse model.

Investigator:

Carlos Cruchaga

Title:

Functional characterization of brain circular RNAs in Alzheimer disease using induced pluripotent stem cell models

Date of Request:

04/04/2023

Aim 1:

To analyze the role of circHOMER1 in AD-related molecular phenotypes using cellular models

Investigator:

RANDALL J BATEMAN

Title:

DIAN-TU-001 Clinical Core Statistical Analysis Plan (SAP) for biochemical measures of amyloid and tau phosphorylation in the brain, and their correlation with clinical, cognitive, and other imaging/CSF outcomes

Date of Request:

01/17/2023

Aim 1:

Specific Aim 1: To biochemically quantify the amount of soluble and insoluble amyloid-beta and tau species in specific regions of the frozen brain regions by mass spectrometry in DIAN-TU, DIAN-Obs and non-AD age-matched controls. Additional biochemical measures of other biomolecules, for example, alpha synuclein, APP, ApoE, inflammatory markers, synaptic & neuronal markers will also be explored.

Aim 2:

Specific Aim 2: Compare the amounts of soluble and insoluble amyloid-beta and tau species between active gantenerumab, active solanezumab, placebo (those from the DIAN-TU placebo arm who did not continue in the gantenerumab Open Label Extension, when available), and control cases (including DIAN-Obs and non-AD controls) to determine effects of drug treatment on amyloid-beta and tau species. Active drug data will be compared with placebo and controls, not with other drug data.

Aim 3:

Specific Aim 3: To quantify by immunohistochemistry the amount of amyloid-beta deposition, tau pathology, astrocytosis, microgliosis, alpha-synucleinopathy, and TDP-43 proteinopathy in multiple neuroanatomic regions of the formalin-fixed brain tissue samples from DIAN-TU and DIAN-Obs participants and their family members, and non-AD age-matched controls. Additional immunohistochemistry measures of other biomolecules, for example, APP, ApoE, inflammatory markers, synaptic & neuronal markers will also be explored.

Aim 4:

Specific Aim 4: Evaluate how amyloid-beta and tau species in insoluble and soluble fractions of the brain and pathologic features measured by immunohistochemistry in formalin-fixed brain tissue are correlated with each other, as well as with the cross-sectional value and longitudinal changes in other imaging/CSF biomarkers (e.g., amyloid PET, tau PET, CSF amyloid-beta, total tau, and phospho-tau), and with clinical and cognitive outcomes, and how these correlations are altered by the active treatments.

Investigator:

Tammie Benzinger

Title:

Quantification of Neuroinflammation in Autosomal Dominant Alzheimer's Disease Using Small-block Brain Specimen imaged by Diffusion Basis Spectrum Imaging (DBSI)

Date of Request:

08/16/2022

Aim 1:

assess the value of DBSI for the study of ADAD by comparing post-mortem MRI signals with histologic data

Investigator:

David Gate

Title:

Comparing active and passive Abeta vaccination by spatial transcriptomics

Date of Request:

07/25/2022

Aim 1:

Identify spatial transcriptomic changes associated with Aβ vaccination.

Investigator:

Jinlong Yu

Title:

Install APP A673T mutation for treatment of AD

Date of Request:

05/20/2022

ID:

DR_022

Aim 1:

To optimize the base editor condition in AD patients IPSC derived neurons.

Aim 2:

Test if the additional E674K mutation base editing introduced modulates the Aβ peptides production and Aβ peptides ‘s toxicity

Investigator:

Ifrah zawar

Title:

Csf biomarkers in seizures among AD patients

Date of Request:

04/11/2022

Status:

Closed

ID:

DR_020

Aim 1:

To study the differences in csf biomarkers in AD patients with and without seizures

Investigator:

Bateman/Benzinger

Title:

ASNR White Paper on ARIA

Date of Request:

02/08/2022

Aim 1:

Training of Radiologists and Neuroradiologists

Aim 2:

Enhance physician understanding of ARIA in order to improve detection and reporting. Additionally, the objective is to provide physicians with imaging examples of the severity grading of ARIA as well as pointing out potential pitfalls in interpretation

Investigator:

Giuseppina Tesco

Title:

Study of endolysosomal alterations (including exosomes) in brain cells cultures derived from fDA iPSC lines and isogenic controls

Date of Request:

01/24/2022

Status:

Referred to Obs

Aim 1:

Study of endolysosomal alterations (including exosomes) in brain cells cultures derived from fDA iPSC lines and isogenic controls

Investigator:

Colin Masters

Title:

CSF Abeta42 and p-tau level review

Date of Request:

12/08/2021

ID:

DR_018

Aim 1:

To provide further information regarding ex-participant 3031007's mutation and pathogenic status. V2 28 May15 CSF Abeta42 and p-tau levels to be reviewed.

Investigator:

Jan Torleif Pedersen, PhD MSc

Title:

Investigation of pS396-tau in samples from DIAN-TU biobank

Date of Request:

12/03/2021

Status:

Referred to Obs

ID:

DR_017

Aim 1:

To investigate pS396-tau levels in CSF samples from DIAN-TU

Aim 2:

To investigate pT217-tau levels in CSF samples from DIAN-TU

Aim 3:

To establish potential correlation between pS396-tau, pT217-Tau and clinical progression parameters

Aim 4:

To investigate tau species in post-mortem brain material targeted by Lu AF87908

Investigator:

Antonio Boza-Serrano

Title:

Galectin-3 as a prognostic biomarker to monitor Autosomal dominant Alzheimer Disease’s progression and response to gantenerumab.

Date of Request:

10/29/2021

Status:

Pending

ID:

DR_015

Aim 1:

To evaluate if gal3 levels in ADAD samples might track /monitor the progression of AD pathology and whether or not gal3 levels are altered under the different treatment evaluated with the patients (gantenerumab)

Aim 2:

To compare the levels of gal3 with the classic biomarkers of pathology progression (amyloid-beta 42, total tau, p-tau181, NfL and PIB-Pet) evaluated in CSF and serum over the DIAN-TU study in placebo, ganterenumab treated patients.